{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:40Z","timestamp":1786118920430,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The test-negative design (TND) has become a widely used observational study design for evaluating vaccine effectiveness, especially during the COVID-19 pandemic. Traditionally, TND has been viewed as a variant of the case-control study and largely limited to use with logistic regression models. In this paper, we first establish that TND can be framed as a special case of a cohort study, thereby opening the door to a wider range of analytical approaches. We then introduce the Prentice, Williams, and Peterson gap-time (PWP-GT) frailty model as a novel method for analyzing TND data, accounting for recurrent infections and time-dependent vaccination status. Through extensive simulation studies, we demonstrate that the proposed model outperforms conventional models commonly applied in TND-based vaccine effectiveness studies. Finally, we apply our method to data from the National COVID Cohort Collaborative, estimating the effectiveness of full and booster doses of Pfizer\u2019s COVID-19 vaccines against both initial infection and reinfection during the Omicron variant circulation period in a real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ede.0000000000001972","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:03:36Z","timestamp":1776863016000},"page":"417-426","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Improving Assessment of Vaccine Effectiveness by Coupling Test-negative Design Studies with Survival Models"],"prefix":"10.1097","volume":"37","author":[{"given":"Shangchen","family":"Song","sequence":"first","affiliation":[{"name":"Department of Biostatistics, College of Public Health and Health Professions, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt D. T.","family":"Hitchings","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, College of Public Health and Health Professions, University of Florida, Gainesville, FL"},{"name":"Emerging Pathogens Institute, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Statistics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5145-7404","authenticated-orcid":false,"given":"Ira M.","family":"Longini","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, College of Public Health and Health Professions, University of Florida, Gainesville, FL"},{"name":"Emerging Pathogens Institute, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the N3C consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"R1-20260529","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1016\/j.vaccine.2006.10.002","article-title":"Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.","volume":"25","author":"Skowronski","year":"2007","journal-title":"Vaccine"},{"key":"R2-20260529","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/EDE.0000000000001116","article-title":"The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology.","volume":"31","author":"Chua","year":"2020","journal-title":"Epidemiology (Cambridge, Mass.)"},{"key":"R3-20260529","doi-asserted-by":"crossref","first-page":"1195908","DOI":"10.3389\/fpubh.2023.1195908","article-title":"Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies.","volume":"11","author":"Song","year":"2023","journal-title":"Front Public Health"},{"key":"R4-20260529","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMe2113151","article-title":"Covid-19 vaccine effectiveness and the test-negative design.","volume":"385","author":"Dean","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20260529","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2024.5633","article-title":"Test-negative study designs for evaluating vaccine effectiveness.","volume":"332","author":"Dean","year":"2024","journal-title":"JAMA"},{"key":"R6-20260529","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/kww064","article-title":"Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness.","volume":"184","author":"Sullivan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"R7-20260529","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","article-title":"The test-negative design for estimating influenza vaccine effectiveness.","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"R8-20260529","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/aje\/kwac203","article-title":"Current challenges with the use of test-negative designs for modeling COVID-19 vaccination and outcomes.","volume":"192","author":"Shi","year":"2023","journal-title":"Am J Epidemiol"},{"key":"R9-20260529","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2024.04.049","article-title":"A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.","volume":"42","author":"Song","year":"2024","journal-title":"Vaccine"},{"key":"R10-20260529","first-page":"100025","article-title":"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study.","volume":"1","author":"Hitchings","year":"2021","journal-title":"Lancet Reg Health Am"},{"key":"R11-20260529","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant.","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"R12-20260529","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41541-023-00716-9","article-title":"The need for a clinical case definition in test-negative design studies estimating vaccine effectiveness.","volume":"8","author":"Sullivan","year":"2023","journal-title":"npj Vaccines"},{"key":"R13-20260529","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/biomet\/65.1.153","article-title":"Retrospective studies and failure time models.","volume":"65","author":"Prentice","year":"1978","journal-title":"Biometrika"},{"key":"R14-20260529","doi-asserted-by":"crossref","first-page":"104734","DOI":"10.1016\/j.ebiom.2023.104734","article-title":"Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study.","volume":"95","author":"Altarawneh","year":"2023","journal-title":"EBioMedicine"},{"key":"R15-20260529","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase.","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"R16-20260529","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection.","volume":"386","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"key":"R17-20260529","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.vaccine.2015.11.077","article-title":"Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains.","volume":"34","author":"Kim","year":"2016","journal-title":"Vaccine"},{"key":"R18-20260529","doi-asserted-by":"crossref","first-page":"13480","DOI":"10.1128\/JVI.02434-13","article-title":"Impact of prior seasonal H3N2 influenza vaccination or infection on protection and transmission of emerging variants of influenza A(H3N2)v virus in ferrets.","volume":"87","author":"Houser","year":"2013","journal-title":"J Virol"},{"key":"R19-20260529","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/v14030470","article-title":"Opposing effects of prior infection versus prior vaccination on vaccine immunogenicity against influenza A(H3N2) viruses.","volume":"14","author":"Fox","year":"2022","journal-title":"Viruses"},{"key":"R21-20260529","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1473-3099(23)00060-9","article-title":"Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.","volume":"23","author":"Tan","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"R22-20260529","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1473-3099(23)00424-3","article-title":"The superiority of bivalent over monovalent booster vaccines.","volume":"23","author":"Arbel","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"R23-20260529","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1198\/1061860031365","article-title":"Penalized survival models and frailty.","volume":"12","author":"Therneau","year":"2003","journal-title":"J Comput Graph Stat"},{"key":"R24-20260529","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the regression analysis of multivariate failure time data.","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika"},{"key":"R25-20260529","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1002\/sim.2434","article-title":"Repeated events survival models: the conditional frailty model.","volume":"25","author":"Box-Steffensmeier","year":"2006","journal-title":"Stat Med"},{"key":"R26-20260529","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B (Methodol)"},{"key":"R27-20260529","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling recurrent events: a tutorial for analysis in epidemiology.","volume":"44","author":"Amorim","year":"2015","journal-title":"Int J Epidemiol"},{"key":"R29-20260529","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models.","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika"},{"key":"R31-20260529","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jamia\/ocaa196","article-title":"The national COVID cohort collaborative (N3C): rationale, design, infrastructure, and deployment.","volume":"28","author":"Haendel","year":"2021","journal-title":"J Am Med Inform Assoc"},{"key":"R32-20260529","doi-asserted-by":"crossref","first-page":"e2022057634","DOI":"10.1542\/peds.2022-057634","article-title":"Vaccine effectiveness of BNT162b2 against delta and omicron variants in adolescents.","volume":"150","author":"Buchan","year":"2022","journal-title":"Pediatrics"},{"key":"R33-20260529","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic omicron infections.","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"R34-20260529","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1038\/s41467-022-31469-z","article-title":"Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults.","volume":"13","author":"Rennert","year":"2022","journal-title":"Nat Commun"},{"key":"R35-20260529","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1038\/s41467-023-39674-0","article-title":"Bias assessment of a test-negative design study of COVID-19 vaccine effectiveness used in national policymaking.","volume":"14","author":"Graham","year":"2023","journal-title":"Nat Commun"},{"key":"R36-20260529","doi-asserted-by":"crossref","first-page":"10062","DOI":"10.1038\/s41467-024-54404-w","article-title":"Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection.","volume":"15","author":"Wiegand","year":"2024","journal-title":"Nat Commun"},{"key":"R37-20260529","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/aje\/kwae288","article-title":"Potential biases in test-negative design studies of COVID-19 vaccine effectiveness arising from the inclusion of asymptomatic individuals.","volume":"194","author":"Ortiz-Brizuela","year":"2025","journal-title":"Am J Epidemiol"},{"key":"R38-20260529","doi-asserted-by":"crossref","first-page":"dyaf086","DOI":"10.1093\/ije\/dyaf086","article-title":"The potential bias introduced into COVID-19 vaccine effectiveness studies at primary care level due to the availability of SARS-CoV-2 Tests in the general population.","volume":"54","author":"Lani\u00e8ce Delaunay","year":"2025","journal-title":"Int J Epidemiol"},{"key":"R39-20260529","first-page":"arXiv:2406.06980","article-title":"Sensitivity analysis for the test-negative design.","author":"Kundu","year":"2024","journal-title":"arXiv"},{"key":"R40-20260529","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/aje\/kwaa084","article-title":"Temporal confounding in the test-negative design.","volume":"189","author":"Dean","year":"2020","journal-title":"Am J Epidemiol"},{"key":"R41-20260529","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/biostatistics\/2.1.63","article-title":"Conditional logistic analysis of case-control studies with complex sampling.","volume":"2","author":"Langholz","year":"2001","journal-title":"Biostatistics (Oxford, England)"},{"key":"R42-20260529","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-statistics-040320-114441","article-title":"Causality and the Cox regression model.","volume":"9","author":"Martinussen","year":"2022","journal-title":"Annu Rev Stat Appl"},{"key":"R43-20260529","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios.","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology (Cambridge, Mass.)"},{"key":"R44-20260529","doi-asserted-by":"crossref","first-page":"e063935","DOI":"10.1136\/bmjopen-2022-063935","article-title":"Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans.","volume":"12","author":"Young-Xu","year":"2022","journal-title":"BMJ Open"},{"key":"R45-20260529","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2207082","article-title":"Protection against Omicron from vaccination and previous infection in a prison system.","volume":"387","author":"Chin","year":"2022","journal-title":"N Engl J Med"},{"key":"R46-20260529","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar.","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"R47-20260529","doi-asserted-by":"crossref","first-page":"ofz195","DOI":"10.1093\/ofid\/ofz195","article-title":"Multiple influenza virus infections in 4 consecutive epidemiological seasons: a retrospective study in children and adolescents.","volume":"6","author":"M\u00f6st","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R48-20260529","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1017\/S0950268822001157","article-title":"Epidemiology of repeat influenza infection in Queensland, Australia, 2005-2017.","volume":"150","author":"Price","year":"2022","journal-title":"Epidemiol Infect"}],"container-title":["Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/EDE.0000000000001972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:08:08Z","timestamp":1786036088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/EDE.0000000000001972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ede.0000000000001972","relation":{},"ISSN":["1044-3983","1531-5487"],"issn-type":[{"value":"1044-3983","type":"print"},{"value":"1531-5487","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}